OTOBIONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OTOBIONE (OTOBIONE).
OTOBIONE is a combination product containing ciprofloxacin (a fluoroquinolone antibiotic) and fluocinolone acetonide (a corticosteroid). Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial cell death. Fluocinolone acetonide suppresses inflammation by binding to glucocorticoid receptors, inhibiting phospholipase A2, and reducing prostaglandin and leukotriene synthesis.
| Metabolism | Ciprofloxacin is partially metabolized in the liver via CYP1A2 and also undergoes renal excretion; fluocinolone acetonide is metabolized via CYP3A4-mediated hydroxylation and reduction, with subsequent glucuronidation and sulfation. |
| Excretion | Renal: 90% unchanged; biliary: <5% as metabolites; fecal: <2% |
| Half-life | 2.5 hours (prolonged to 12-24 hours in renal impairment, CrCl <30 mL/min) |
| Protein binding | 20% (primarily albumin) |
| Volume of Distribution | 0.3 L/kg (restricted to extracellular fluid; negligible CNS penetration) |
| Bioavailability | Topical otic: <5% systemic absorption (intact tympanic membrane); Oral: not applicable |
| Onset of Action | Topical: 15 minutes (otitis externa); Otic drops: 30-60 minutes for local anti-inflammatory effect |
| Duration of Action | 6-8 hours (topical); therapeutic levels maintained for 12 hours with twice-daily dosing |
1-2 drops in affected ear(s) twice daily; otic administration only.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | 1-2 drops in affected ear(s) twice daily; otic use only. Safety and efficacy in children <1 year not established. |
| Geriatric use | No specific dose adjustment; use same as adult dosing. Caution in reduced hepatic/renal function if systemic absorption suspected. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OTOBIONE (OTOBIONE).
| Breastfeeding | Minimal excretion into breast milk; M/P ratio unknown. Use with caution, monitor infant for diarrhea and rash. |
| Teratogenic Risk | FDA Category C. No adequate human studies; animal studies suggest risk. Avoid in first trimester unless benefit outweighs risk. Potential for ototoxicity in fetus if used near term. |
| Fetal Monitoring | Monitor maternal renal function, hearing (audiometry) and vestibular function. Fetal ultrasound for growth restriction if used long-term. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to ciprofloxacin, fluocinolone acetonide, or any component of the formulation","Viral infections of the external ear including herpes simplex or varicella-zoster","Fungal infections of the ear without appropriate concomitant antifungal therapy","Perforated tympanic membrane (relative contraindication; use only if benefits outweigh risks)"]
| Precautions | ["For otic use only; not for injection or ophthalmic use","Hypersensitivity reactions including anaphylaxis have been reported with ciprofloxacin","Prolonged use may result in overgrowth of non-susceptible organisms including fungi","If infection persists after a full course of therapy, discontinue use and reevaluate","Corticosteroids may mask signs of infection or cause worsening of existing infections","Avoid use in patients with a history of hypersensitivity to any component, fluoroquinolones, or corticosteroids"] |
Loading safety data…
| Fertility Effects | No known adverse effects on human fertility. Animal studies show no impairment. |